argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
| Revenue (TTM) | $5.32B |
| Gross Profit (TTM) | $3.14B |
| EBITDA | $1.61B |
| Operating Margin | 32.00% |
| Return on Equity | 23.60% |
| Return on Assets | 11.60% |
| Revenue/Share (TTM) | $3.44 |
| Book Value | $5.38 |
| Price-to-Book | 7.03 |
| Price-to-Sales (TTM) | 10.01 |
| EV/Revenue | 10.47 |
| EV/EBITDA | 30.68 |
| Quarterly Earnings Growth (YoY) | 95.20% |
| Quarterly Revenue Growth (YoY) | 59.30% |
| Shares Outstanding | $62.89M |
| Float | $1.56B |
| % Insiders | 0.00% |
| % Institutions | 46.12% |
Volatility is currently expanding
October 15, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that it will host a conference call and audio webcast on Thursday, October 22, 2026 at 2:30 PM CET (8:30 AM ET) to discuss its third quarter 2026 financial results and provide a business update.
ARGX's FB102 achieves its primary endpoint in a phase II celiac disease study, paving the way for late-stage development despite a nearly 12% stock drop.
argenx shares tumble 12% after discontinuing its late-stage Sjogren's disease study, while positive FB102 data in celiac disease offer a contrasting pipeline development.
argenx shares fell after halting its Phase 3 Sjögren's trial, but the selloff appears to overstate the lost opportunity. VYVGART franchise remains robust, driving strong cash generation and funding pipeline advancements, despite setbacks in expanding indications. At ~8x annualized sales, ARGX trades at a discount to peers like Vertex, supporting a reiterated 'Buy' rating based on growth prospects.
ARGX share price fell sharply after a futility finding resulted in the discontinuation of a pending Phase 3 trial. SueWallSt notifies investors of a pending investigation.
Halozyme wins a Dutch court order blocking Merck's Keytruda SC in eight European markets, strengthening its position in the patent dispute.
Shares in argenx SE (NASDAQ:ARGX) fell nearly 15% in New York on Thursday after it discontinued a late-stage trial of its drug Vyvgart in Sjögren's disease. Sjögren's disease is a chronic autoimmune condition characterized by immune-mediated destruction of the glands that produce tears and saliva, causing symptoms including dry eyes and mouth.
The stock was down 18%, wiping out year-to-date gains after the biotech stopped a late-stage clinical trial of its Vyvgart drug due to lack of efficacy.
Study met primary endpoint of change from baseline in the ratio of Vh:Cd (p= 0.0176 ) First Phase 2 evidence that blocking CD122 can prevent gluten-induced intestinal damage in people living with celiac disease argenx plans to advance FB102 into Phase 3 development October 8, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced positive topline results from the Phase 2 study evaluating FB102, a first-in-class CD122 inhibitor, in adults with celiac disease. These results represent the first clinical readout of FB102 following argenx's acquisition of Forte Biosciences in August 2026.
October 8, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that it will discontinue the Phase 3 UNITY study of efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with moderate-to-severe Sjögren's disease. The decision is based on the recommendation from an Independent Data Monitoring Committee (IDMC) to stop the study for futility following an interim analysis.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ARGX and any ticker you trade — then tracks every position and per-strategy win rate.
